Recent Company News

• 02:38 AM ET Sep 19, 2025
  

  Chugai Pharmaceutical receives approval for additional indication of Tecentriq in Japan (¥6826.0000, 0)

• 09:06 AM ET Sep 17, 2025
  

  Eli Lilly announces topline results from ACHIEVE-3, meets primary endpoint ($760.13, 0.00)

• 06:08 PM ET Sep 16, 2025
  

  Eli Lilly reports detailed results from Phase 3 ATTAIN-1 trial, the investigational once-daily oral pill led to average weight loss of 27.3 lbs (12.4%) at highest dose at week 72 in the Phase 3 study ($764.71, 0.00)

• 11:54 PM ET Aug 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:33 PM ET Aug 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 06:05 AM ET Aug 18, 2025
  

  Natera announces positive topline results from Phase III IMvigor011 clinical trial ($163.02, 0.00)

• 03:11 AM ET Jul 24, 2025
  

  Chugai Pharmaceutical reports H1 core net income attributable ¥94.3B, (17%) vs year-ago ¥113.5B (¥7238.0000, 0)

• 02:16 AM ET Jul 24, 2025
  

  Roche reports H1 results; StreetAccount notes the H1 report includes financial performance metrics for Chugai Pharmaceutical (¥7258.0000, +141)